← Back to headlines
Analysts Anticipate Upbeat Q2 for Johnson & Johnson Despite Stelara Headwinds
Analysts are forecasting a positive second-quarter earnings report for Johnson & Johnson, even as the company faces challenges related to its drug Stelara.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Luigi Mangione Pleads Guilty to Killing UnitedHealthcare CEO Brian Thompson
23m ago
Water Levels Rise at Paks, Economic Concerns Over Low Water in Germany
50m ago
Montenegrin Unions Urge Government to Begin Negotiations on New General Collective Agreement
1h ago
Deutsche Bahn Reactivates Old Freight Wagons Amid Low Rhine Water Levels
1h ago